Community engagement and clinical trial diversity: Navigating barriers and co-designing solutions-A report from the "Health Equity through Diversity" seminar series.
Community engagement and clinical trial diversity: Navigating barriers and co-designing solutions-A report from the "Health Equity through Diversity" seminar series.
复制标题
DOI：
10.1371/journal.pone.0281940
复制
发表时间：
2023
期刊：
影响因子：
3.7
通讯作者：
中科院分区：
文献类型：
--
作者：
近年来，人们越来越意识到临床试验参与者缺乏多样性。在测试新的治疗和非治疗干预措施以确保整个人群的安全性和有效性时，公平的代表性是关键。不幸的是，在美国（US），与白色人群相比，种族和少数民族人群在临床试验中的代表性仍然不足。举办了题为“通过多样性实现健康公平”的四部分系列网络研讨会，讨论通过多样化临床试验和解决社区中的医疗不信任问题来促进健康公平的解决方案。每个网络研讨会长达1.5小时，从小组讨论开始，然后是分组讨论室，主持人主持与健康公平相关的讨论，抄写员记录每个房间的对话。小组成员的不同群体包括社区成员，公民代表，临床科学家和生物制药代表。从讨论中收集抄写笔记，并按主题进行分析，以揭示中心主题。前两次网络研讨会分别有242人和205人参加。与会者代表了美国25个州，美国以外的4个国家，并分享了各种背景，包括社区成员，临床医生/研究人员，政府组织，生物技术/生物制药专业人员等。参与临床试验的障碍大致分为以下几个主题：获取、意识、歧视和种族主义以及劳动力多样性。与会者指出，创新的、社区参与的、共同设计的解决方案至关重要。尽管少数种族和族裔群体占美国人口的近一半，但临床试验中的代表性不足仍然是一个关键挑战。社区参与了本报告中详细介绍的共同开发的解决方案，以解决获取，意识，歧视和种族主义问题，以及劳动力多样性对促进临床试验多样性至关重要。
In recent years, there has been increasing awareness of the lack of diversity among clinical trial participants. Equitable representation is key when testing novel therapeutic and non-therapeutic interventions to ensure safety and efficacy across populations. Unfortunately, in the United States (US), racial and ethnic minority populations continue to be underrepresented in clinical trials compared to their White counterparts. Two webinars in a four-part series, titled “Health Equity through Diversity,” were held to discuss solutions for advancing health equity through diversifying clinical trials and addressing medical mistrust in communities. Each webinar was 1.5 hours long, beginning with panelist discussions followed by breakout rooms where moderators led discussions related to health equity and scribes recorded each room’s conversations. The diverse groups of panelists included community members, civic representatives, clinician-scientists, and biopharmaceutical representatives. Scribe notes from discussions were collected and thematically analyzed to uncover the central themes. The first two webinars were attended by 242 and 205 individuals, respectively. The attendees represented 25 US states, four countries outside the US, and shared various backgrounds including community members, clinician/researchers, government organizations, biotechnology/biopharmaceutical professionals, and others. Barriers to clinical trial participation are broadly grouped into the themes of access, awareness, discrimination and racism, and workforce diversity. Participants noted that innovative, community-engaged, co-designed solutions are essential. Despite racial and ethnic minority groups making up nearly half of the US population, underrepresentation in clinical trials remains a critical challenge. The community engaged co-developed solutions detailed in this report to address access, awareness, discrimination and racism, and workforce diversity are critical to advancing clinical trial diversity.
登录
查看更多内容
影响因子：
37.8
作者：
Churchwell, Keith;Elkind, Mitchell S. V.;Williams, Olajide
通讯作者：
Williams, Olajide
影响因子：
2.6
作者：
Bierer BE;White SA;Gelinas L;Strauss DH
通讯作者：
Strauss DH
DOI：
10.1525/jer.2007.2.4.69
发表时间：
2007-12-01
影响因子：
1.3
作者：
Breese, Peter E.;Burman, William J.;Weis, Stephen E.
通讯作者：
Weis, Stephen E.
影响因子：
3.2
作者：
Frierson, Georita M.;Pinto, Bernardine M.;Jaffe, Alex D.
通讯作者：
Jaffe, Alex D.
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group